Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of VX-118 in Healthy Adults
NCT06312787Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VX-118 in cystic fibrosis (CF) (3 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration Versus Time Curve. Started Apr 2024; status: completed.
02
Drugs
VX-118
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06312787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312787.